Suppr超能文献

在计算机化医师医嘱录入系统和临床决策支持下,肾药师进行药物治疗审核的获益。

Benefit of medication reviews by renal pharmacists in the setting of a computerized physician order entry system with clinical decision support.

机构信息

Hospital Pharmacy, University Hospital, LMU Munich, Munich, Germany.

Doctoral Program Clinical Pharmacy, University Hospital, LMU Munich, Munich, Germany.

出版信息

J Clin Pharm Ther. 2022 Oct;47(10):1531-1538. doi: 10.1111/jcpt.13697. Epub 2022 Jul 22.

Abstract

WHAT IS KNOWN AND OBJECTIVE

A 'renal pharmacist consultant service' (RPCS) reviewing patients' charts with renal impairment (RI) for drug-related problems (DRP) can foster patient safety. However, the benefit of this service in the new setting of a computerized physician order entry (CPOE)-system with a clinical decision support (CDS)-system is unknown. The aim of our study was to evaluate the general need for an RPCS on wards with a CPOE-CDS-system already in use and its effectiveness on prescription changes to ensure in-hospital patient safety.

METHODS

Over a period of 3 months (02-04/2021), elective orthopaedic and trauma patients with eGFR /CrCl <60 ml/min at a German University Hospital received a medication review by a renal pharmacist for all medication entered into the CPOE-system (Meona®) by the treating physicians. Written consultations explaining identified DRP and recommending interventions to solve them, for example, dose or drug adaptation, were shared with the physicians directly in the drug chart tab of Meona®. In complex cases, DRP were additionally discussed via phone. The prescription changes were evaluated retrospectively.

RESULTS AND DISCUSSION

During 53 working days, 712 (30.5%) of 2331 screened patients were included with an eGFR /CrCl <60 ml/min and a pharmacist-led medication review was performed for all medication presented in the CPOE-system (Meona®). In 79 of 712 (11.1%) patients, one or more DRP were detected (median 1 DRP (1-3) per patient) and written recommendations concerning 106 of 1090 (9.7%) drugs were shared via Meona®. In total, 104 DRP were identified, mostly caused by 'dosage too high' (n = 55, 52.9%), 'dosage regime wrong' (n = 13, 12.5%), and 'contraindication' (n = 9, 8.7%). Acceptance rate of recommendations was 74.0% (n = 77/104). In nine cases (8.7%), despite of specific recommendations, no adjustment of drugs was made because of lack of alternatives. In 11 (10.6%) cases, prescription remained unchanged for unknown reasons and in seven (6.7%) cases, the result was unknown due to discharge.

WHAT IS NEW AND CONCLUSION

In the setting of prescribing in a CPOE-CDS-system, that provides physicians with advice for drug or dose adaption, the pharmacist-led medication reviews still identified DRP in orthopaedic and trauma patients with RI. A RPCS forwarding recommendations to solve DRP via the electronic medical record increased appropriate prescribing by physicians and, thus, may further improve patient safety.

摘要

已知和目的

审查有肾损伤(RI)相关药物问题(DRP)的患者图表的“肾脏药剂师顾问服务”(RPCS)可以促进患者安全。然而,在使用计算机化医嘱录入系统(CPOE)和临床决策支持系统(CDS)的新环境中,这种服务的益处尚不清楚。我们的研究目的是评估在已经使用 CPOE-CDS 系统的病房中对 RPCS 的一般需求及其在确保住院患者安全方面对处方更改的有效性。

方法

在德国大学医院,在 3 个月(2021 年 2 月至 4 月)期间,接受矫形和创伤科治疗的 eGFR/CrCl <60ml/min 的择期患者接受了肾脏药剂师对所有进入 CPOE 系统(Meona®)的药物进行的药物审查。书面咨询解释了已识别的 DRP,并建议通过调整剂量或药物来解决这些问题,例如,调整剂量或药物。在复杂情况下,还通过电话讨论了 DRP。回顾性评估处方更改。

结果与讨论

在 53 个工作日期间,对 2331 名筛查患者中的 712 名(30.5%)进行了筛选,对所有在 CPOE 系统(Meona®)中呈现的药物进行了药剂师主导的药物审查。在 712 名患者中的 79 名(11.1%)患者中发现了一个或多个 DRP(中位数为每位患者 1 个 DRP(1-3)),并通过 Meona®共享了有关 1090 种药物中的 106 种药物的 106 份书面建议。总共发现了 104 个 DRP,主要由“剂量过高”(n=55,52.9%)、“剂量方案错误”(n=13,12.5%)和“禁忌症”(n=9,8.7%)引起。建议的接受率为 74.0%(n=77/104)。在 9 个案例(8.7%)中,尽管有具体建议,但由于缺乏替代品,仍未调整药物。在 11 个案例(10.6%)中,由于未知原因处方未作更改,在 7 个案例(6.7%)中,由于出院,结果未知。

创新与结论

在开具 CPOE-CDS 系统医嘱的环境中,该系统为医生提供了关于药物或剂量调整的建议,肾脏药剂师主导的药物审查仍然确定了 RI 矫形和创伤患者的 DRP。通过电子病历转发解决 DRP 的建议的 RPCS 增加了医生的适当处方,从而可能进一步提高患者安全性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验